ResearchBIORXIVMar 30
Scientists discovered that a gene called WAPL, which helps control how DNA is organized in cells, may cause a rare genetic disorder when it doesn't work properly. This is important because doctors previously thought only certain other genes in the same family could cause this type of disease. The researchers studied patients with this condition and did lab tests to prove WAPL is responsible for a genomic disorder affecting chromosome 10.
WHY IT MATTERSIf you or your child has developmental delays, intellectual disability, or birth defects without a genetic diagnosis, this discovery means WAPL gene testing could now identify the cause in previously undiagnosed patients.
ResearchBIORXIVMar 30
Researchers studied how child abuse and accidental injuries affect DNA in different ways. They looked at saliva samples from children with injuries and used advanced technology to find specific DNA changes that appear in abused children but not in those with accidental injuries. This research could help doctors identify abuse cases earlier and understand how trauma affects children's bodies at a biological level.
WHY IT MATTERSIf validated, this epigenetic signature could provide doctors with an objective biological marker to help distinguish abuse from accidental injury in children presenting with traumatic injuries, potentially improving identification and intervention in suspected maltreatment cases.
ResearchPUBMEDMar 28
Scientists are studying a new way to treat corneal scarring (clouding of the eye that causes blindness) using tiny particles called extracellular vesicles that come from immune cells called macrophages. This approach is being tested for rare genetic eye diseases like epidermolysis bullosa, KID syndrome, and aniridia, where the cornea becomes scarred due to chronic inflammation and genetic mutations. Current treatments don't work well and have significant side effects, so this new method could offer patients a better option.
WHY IT MATTERSFor patients with epidermolysis bullosa, KID syndrome, or aniridia experiencing corneal scarring, this research offers a potential new treatment strategy that could prevent blindness without the side effects of current therapies.
ResearchPUBMEDMar 28
Scientists are getting better at finding rare genetic diseases using a tool called next-generation sequencing, which can read a person's DNA quickly and accurately. They're also developing new medicines called antisense oligonucleotides that can be customized for each patient to fix problems caused by genetic mutations. Together, these advances mean doctors can diagnose rare diseases faster and create personalized treatments tailored to each person's specific genetic makeup.
WHY IT MATTERSThis research shows a clear path for patients with rare genetic diseases to move from diagnosis to personalized treatment within a single medical framework, potentially reducing the diagnostic odyssey that currently takes years for many rare disease patients.
ResearchPUBMEDMar 28
This article discusses rare diseases that affect the major blood vessels in the neck and upper chest (called supra-aortic trunks). While most blockages in these vessels are caused by common heart disease risk factors, about 10% happen in people without those risk factors. The article highlights three newly recognized conditions: TIPIC syndrome (temporary inflammation around the carotid artery), carotid web (an unusual narrowing), and Eagle syndrome (a bone growth problem). Better imaging technology is helping doctors identify these rare conditions more accurately.
WHY IT MATTERSIf you have unexplained neck pain, stroke symptoms, or carotid artery narrowing without typical heart disease risk factors, your doctor may now consider these emerging diagnoses instead of assuming standard atherosclerosis.
NewsPUBMEDMar 28
This is an editorial article that introduces a special collection of scientific papers about gene therapy for rare diseases. Gene therapy is a treatment that fixes or replaces faulty genes that cause disease. The editorial discusses how gene therapy is becoming an important treatment option for rare diseases that affect small numbers of people.
WHY IT MATTERSThis editorial highlights the growing momentum in gene therapy development for rare diseases, which means more treatment options may become available for conditions that previously had few or no approved therapies.
Clinical trialCLINICALTRIALSMar 27
Researchers are testing a cancer drug called trastuzumab deruxtecan (T-DXd) in patients with several types of rare and uncommon cancers that have a specific protein marker called HER2. The study includes seven different cancer types in the first part, including bladder, bile duct, cervical, uterine, ovarian, and pancreatic cancers. This drug has already shown promise in breast and stomach cancers, and doctors want to see if it works in these other cancer types too.
WHY IT MATTERSThis trial offers patients with HER2-positive rare cancers like biliary tract, cervical, endometrial, ovarian, and pancreatic cancer access to a targeted therapy that has demonstrated effectiveness in other cancer types—potentially providing a new treatment option where few exist.
ResearchCLINICALTRIALSMar 27
Researchers are looking for 63 participants to help them understand how DNA changes in babies before birth compare to DNA changes after birth. They want to collect DNA from amniotic fluid (the fluid around a baby in the womb) or from tissue samples after delivery to create a reference guide. This guide will help doctors better diagnose rare genetic diseases that start before birth.
WHY IT MATTERSThis trial could improve how doctors diagnose rare genetic diseases in fetuses and newborns by establishing what normal DNA patterns look like before birth, which is currently unknown.
Clinical trialCLINICALTRIALSMar 27
Researchers in France are recruiting 5,000 newborns to test a new way of screening for rare diseases using genome sequencing—a complete reading of a baby's DNA. Instead of the current blood spot tests that check for only a few dozen conditions, this study will see if reading a baby's entire genome can safely and effectively find many more rare genetic diseases at birth. This is one of the first major studies in Europe to test this approach.
WHY IT MATTERSThis trial could expand newborn screening in France to detect dozens of additional rare genetic diseases at birth, potentially allowing earlier treatment and better health outcomes for babies with conditions that currently go undiagnosed until symptoms appear.
Clinical trialCLINICALTRIALSMar 27
Researchers are testing a new combination treatment for metastatic Merkel cell carcinoma, a rare type of skin cancer. The study combines a drug called avelumab with either a radioactive therapy or radiation treatment. The trial is currently enrolling patients and aims to see if this combination is safe and effective at fighting the cancer.
WHY IT MATTERSThis trial offers patients with metastatic Merkel cell carcinoma access to a novel combination therapy that may provide additional treatment options beyond standard care, though enrollment is currently closed.
Clinical trialCLINICALTRIALSMar 27
Researchers are looking for 1,000 people of any age who have a rare blood disorder called FPDMM, which is caused by a change in the RUNX1 gene. People with this condition may bleed easily and for longer than normal when injured. This study will help doctors better understand the disease, diagnose it more accurately, and find better ways to treat it.
WHY IT MATTERSThis is an active recruiting trial sponsored by the National Human Genome Research Institute seeking 1,000 participants with RUNX1-variant FPDMM — participation could directly advance understanding of diagnosis and treatment for this rare inherited bleeding disorder.
ResearchBIORXIVMar 27
Researchers studied how getting a genetic diagnosis through whole genome sequencing (a test that reads all of a person's genes) affects how much healthcare seriously ill children need over time. They looked at medical records from children in the UK between 2016 and 2020 to see if knowing the genetic cause of their illness changed how often they visited doctors, went to the hospital, or needed other medical care.
WHY IT MATTERSIf you have a seriously ill child undergoing genetic testing, this research will help show whether getting a diagnosis actually changes how your child's care is managed and how often you'll need medical visits going forward.
AdvocacyPRESS RELEASEMar 26
The National Organization for Rare Disorders (NORD), a major patient advocacy group, announced new leadership positions focused on policy and government relations. These appointments aim to strengthen NORD's efforts to influence laws and policies that affect people with rare diseases. The moves show NORD is expanding its work to advocate for patients at the federal and global levels.
WHY IT MATTERSStronger policy leadership at NORD means patients with rare diseases will have more powerful advocates working directly with Congress and government agencies to push for faster drug approvals, better insurance coverage, and increased research funding.
AdvocacyPRESS RELEASEMar 26
NORD and OpenEvidence announced a partnership to create AI-powered tools that help doctors and patients find reliable information about rare diseases. These tools will use artificial intelligence to organize and review medical information, making it easier for people with rare diseases to access trustworthy resources and get better care.
WHY IT MATTERSThis partnership expands access to expert-reviewed rare disease information through AI technology, potentially helping patients with any rare disease find accurate medical resources and connect with specialists more easily.
AdvocacyRSSMar 26
The National Organization for Rare Disorders (NORD), a major patient advocacy group, announced new leadership positions to strengthen its work in rare disease policy. Michael J. Beard was appointed as Vice President of Federal and Global Public Affairs. These leadership changes are designed to help NORD better represent patients' interests in government and international discussions about rare diseases.
WHY IT MATTERSStronger NORD leadership in policy and advocacy can directly influence which rare diseases get research funding, how quickly new treatments are approved, and what insurance coverage looks like for rare disease patients.
AdvocacyRSSMar 26
NORD, a major rare disease organization, is partnering with OpenEvidence to create AI-powered tools that help doctors and patients find reliable information about rare diseases. This partnership aims to make it easier for people worldwide to access trustworthy resources about their conditions and treatment options.
WHY IT MATTERSThis partnership could help patients with rare diseases get faster access to accurate, expert-reviewed information from their doctors, potentially reducing diagnostic delays and improving treatment decisions.
ResearchBIORXIVMar 26
Scientists discovered a new protein called SR12 in the malaria parasite that works similarly to proteins in human cells. This protein might be a good target for creating new malaria drugs, especially since the parasite is becoming resistant to current treatments. The researchers used computer modeling to understand how this protein is structured and how it functions.
WHY IT MATTERSThis research could lead to new antimalarial drugs that work differently than current ones, which is critical because malaria parasites are increasingly resistant to existing treatments and malaria still kills hundreds of thousands of people annually.
PolicyPUBMEDMar 26
France is creating a new type of healthcare worker called a Genomic Pathway Manager to help doctors order genetic tests for patients with rare diseases and cancer. These managers will make it easier for patients to get genetic testing by organizing the process and helping doctors understand when and how to use these tests. The goal is to make genetic testing available to more people across France starting in 2025.
WHY IT MATTERSIf you have a rare disease in France, this new system could help your doctor identify your condition faster through genetic testing, potentially leading to earlier diagnosis and treatment options.
ResearchPUBMEDMar 26
Doctors who treat children with rare lung diseases in German-speaking countries were surveyed about their experience and confidence in diagnosing and treating these conditions. The study found that while common rare lung diseases like cystic fibrosis have good support systems, many other rare lung diseases don't have clear treatment guidelines. Researchers want to understand what training and resources doctors need to better help children with these uncommon lung problems.
WHY IT MATTERSIf you have a child with a rare lung disease, this research could lead to better training for pediatric lung doctors in your region, potentially reducing diagnostic delays and improving access to specialized care.
AdvocacyPUBMEDMar 26
This study looked at how patient groups led by people with rare diseases help fill gaps in education and awareness in Poland. Researchers interviewed 11 leaders of these patient groups to understand how they act as 'ambassadors' and 'advocates' to teach doctors, teachers, and the public about rare diseases. The findings show that patient advocacy groups play an important but often overlooked role in helping people understand and navigate rare diseases.
WHY IT MATTERSIf you have a rare disease, this research validates that patient-led advocacy groups are essential resources for getting accurate information and support when healthcare systems and professionals lack rare disease knowledge.